Clinical Trial Update: Phase I Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of HM781-36B in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase I study to determine the maximum tolerated dose and assess safety and pharmacokinetics of HM781-36B in patients with advanced solid tumors. The trial stat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• HM781-36B (HM781-36B)

Snippet

Sponsor: Hanmi Pharmaceutical Company Limited | Conditions: Advanced Solid Tumor | Phase 1 | Status: COMPLETED